CytRx Corporation sells off Molecular Chaperone Drugs to Copenhagen, Denmark-based Orphazyme ApS in its continued efforts to monetize non-oncology assets. This is another example of CytRx’s creative strategies to liquidate non-core assets as a source of non-dilutive financing. If you are interested in more details about this transaction, check out our deal profile below.
- Specialty Pharmaceutical Industry Trading Multiple Analysis
- An Overview of Global Regulatory Trends in the Nutraceutical Industry – April 2013
- Biosimilars: Opportunity Amongst Uncertainty
- Modernizing Pharma Markets in Brazil and Mexico
- The Medical Device Excise Tax (MDET) – Ramifications for Device Makers